‘Dangling’ Accelerated Approvals: US FDA Flags Concerns About ‘Marginal’ Response Rates
Executive Summary
Failed confirmatory trials for PD-1/L-1 inhibitor indications raise questions about marginal response rates in single-arm trials used to support accelerated approval, Oncology Center of Excellence leaders say in NEJM article that explains why the agency is taking six of these indications to its Oncologic Drugs Advisory Committee.
You may also be interested in...
Istodax’s Lymphoma Accelerated Approval Indication Falls Victim To Failed Confirmatory Trial
BMS’ histone deacetylase inhibitor is the first oncology drug outside the PD-1/L1 class to lose an indication under US FDA’s recent review of ‘dangling’ accelerated approvals. Claim for second-line peripheral T-cell lymphoma was withdrawn because first-line study failed to meet its progression-free survival endpoint.
Pepaxto’s Accelerated Approval In Myeloma May Sink On OCEAN Trial's Adverse Survival Data
US FDA is reviewing confirmatory trial data that suggest a ‘detriment in survival’ with Oncopeptides’ alkylating agent in relapsed/refractory multiple myeloma and may convene its Oncologic Drugs Advisory Committee to explore continued marketing for patients who received at least four prior lines of therapy.
Keytruda May Stay Competitive In Gastric Cancer Despite Losing Third-Line Claim
While Opdivo’s first-line approval has altered the treatment landscape, Keytruda may expand its presence there in the next few years with new indications.